Therapeutic strategies encompassing monoclonal antibodies and vaccines to tackle the SARS-CoV-2 omicron variant amongst European children
Pharmazie
; 77(11/12):317-325, 2022.
Article
in English
| CAB Abstracts | ID: covidwho-2267495
ABSTRACT
Omicron is a notable B.1.1.529 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) comprising 50 gene mutations in total, within which 32 gene mutations were recorded on spike 1 (S1) protein. Omicron beholding higher gene mutations than other prevalent SARS-CoV-2 variants of concern, including the Delta-SARS-CoV-2 variant, exhibited the highest transmission efficacy. About 2152 individuals from 57 countries contracted Omicron in the shortest interval of two weeks proclaiming the variant to be the most contagious SARS-CoV-2 variant amongst all other SARS-CoV-2 variants of concern. The first Omicron contracted patient was diagnosed on 24 November 2021 in South Africa, and the South African population was infected presenting these health ailments sore throat, headache, body pain, and mild to severe fatigue commonly witnessed among children and adults. In Germany, together with aged people with co-morbidities and young adults, children of 0-4 yrs and 5-14 yrs were profusely affected by Omicron. Omicron contracted Swedish children showed moderate to severe convulsions as adverse symptoms. In the UK, Omicron positive children in higher numbers were examined and treated under hospital care with ventilators and oxygen cylinders. This narrative insight review illustrates the distinct virulence characteristics of Omicron in evading the human-host neutralizing antibodies action in both SARS-CoV-2 convalescent individuals and immunized population in the context of its outbreak in European children. Moreover, the effect of monoclonal antibodies and the appropriate therapeutic dosage of SARS-CoV-2 vaccines, and the common pediatric vaccines that finds promising to tackle Omicron outbreaks in children across Europe have been unveiled in the review.
Prion; Viral; Bacterial and Fungal Pathogens of Humans [VV210], Host Resistance and Immunity [HH600], Human Immunology and Allergology [VV055], human diseases, coronavirus disease 2019, viral diseases, public health, children, monoclonal antibodies, disease prevalence, disease prevention, epidemiology, headaches, immunization, outbreaks, symptoms, vaccination, vaccines, young adults, immune sensitization, man, Severe acute respiratory syndrome coronavirus 2, Europe, Germany, UK, South Africa, Homo, Hominidae, primates, mammals, vertebrates, Chordata, animals, eukaryotes, Severe acute respiratory syndrome-related coronavirus, Betacoronavirus, Coronavirinae, Coronaviridae, Nidovirales, positive-sense ssRNA Viruses, ssRNA Viruses, RNA Viruses, viruses, European Union Countries, high income countries, OECD Countries, very high Human Development Index countries, Western Europe, British Isles, Commonwealth of Nations, Anglophone Africa, Africa, high Human Development Index countries, Southern Africa, Africa South of Sahara, upper-middle income countries, SARS-CoV-2, viral infections, Britain, United Kingdom, subsaharan Africa
Full text:
Available
Collection:
Databases of international organizations
Database:
CAB Abstracts
Topics:
Vaccines
/
Variants
Language:
English
Journal:
Pharmazie
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS